Dr. Aaron S. Mansfield
Dr. Aaron S. Mansfield is a prolific researcher in the lung cancer and mesothelioma field, publishing five manuscripts between January and March 2019. He earned his medical degree from the University of California Irvine School of Medicine before completing his residency and fellowship. He has been a Clinical Investigator at the Mayo School of Graduate Medical Education since 2013.
Dr. Mansfield studies tumor immunology, early mesothelioma drug development, and thrombosis in cancer. He hopes his research efforts will provide new and better options for cancer treatment. In clinical practice, Dr. Mansfield treats lung cancer, mesothelioma and thymic cancers. His clinic works to provide effective, multi-disciplinary care to all patients, striving to provide clear educational information and allow patients to make informed decisions in their cancer treatment journeys.
Main Specialty: Oncology, Hematology
Other Interests & Specialties: Thoracic malignancies and tumor immunology, non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic malignancies and phase I clinical trials.
Certifications, Awards & Accolades: American Board of Internal Medicine Certifications in Oncology, Hematology and Internal Medicine, 2016 Top Reviewer for Journal of Thoracic Oncology, Excellence in Clinical Teaching from Mayo Clinic Rochester Department of Medicine, Grant Reviewer for A Breath of Hope Lung Foundation, Board Member of the Mesothelioma Applied Research Foundation.
Education & Experience:
- Fellowship in Internal Medicine at Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
- Clinical Investigator of Internal Medicine, Hematology/Medical Oncology at Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
- Residency in Internal Medicine at Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
- Medical Degree from University of California Irvine
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. December 2018;4(12):e01039. doi: 10.1016/j.heliyon.2018.e01039
Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion. Clinical Lung Cancer. November 2018. pii: S1525-7304(18)30298-5. doi: 10.1016/j.cllc.2018.11.002
Mesothelioma Clinical Trials by Aaron S. Mansfield, MD
Dr. Mansfield is associated with the following clinical trials:
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelin Positive; Pleural Malignant Mesothelioma Last Updated: May 27, 2019 Status: Recruiting